235
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Real-world evidence on the use of daratumumab, bortezomib and dexamethasone (DVd) in lenalidomide-refractory myeloma patients: subgroup analysis of the multicenter retrospective experience by “rete ematologica pugliese”

ORCID Icon, , , , , , , , , , , , , , , , , , , , , , & show all
Pages 1715-1718 | Received 24 Nov 2022, Accepted 24 Jun 2023, Published online: 07 Jul 2023

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.